Cytoskeleton-Centric Proteins |
Colorectal cancer |
Macrophages |
Activate cathepsin B/pro-inflammatory cytokine secretion |
Promote inflammation |
Chen et al. (2016)
|
Rab22a-NeoF1 |
Osteosarcoma |
Macrophages |
M2 polarization/STAT3/RhoA activation |
Promote lung metastasis |
Zhong et al. (2021)
|
MFG-E8 |
Prostate cancer |
Macrophages |
M2 polarization/Increase efferocytosis/Suppress proinflammatory response |
Promote tumor progression |
Soki et al. (2014)
|
CMTM6 |
OSCC |
Macrophages |
M2 polarization/ERK1/2 signaling |
Facilitate proliferation, migration and invasion |
Pang et al. (2021)
|
HMGB1 |
Esophageal squamous cell carcinoma |
Macrophages |
M2 polarization/Trigger clonal expansion of PD1+ TAM |
Promote tumor development |
Li et al. (2019)
|
gp130 |
Breast Cancer |
Macrophages |
Activate IL-6/STAT3 signaling |
Establish a pro-tumorigenic cancer microenvironment |
Ham et al. (2018)
|
Chondroitin Sulfate Proteoglycan 4/α-2-Macroglobulin/Lactadherin/EGFR/Integrins |
Glioblastoma multiforme |
Monocytes |
Increase phagocytic capacity/Mediate monocytes differentiation into M2 macrophages |
Resemble the tumor supportive phenotypes |
de Vrij et al. (2015)
|
EIF2/mTOR/Ephrin B |
Glioblastoma |
Macrophage |
M2 phenotype/Increase PD-L1 expression |
Induce immunosuppressive microenvironment |
Gabrusiewicz et al. (2018)
|
Serglycin |
Myeloma |
Target cell |
Reprogram target cells/Increase the migration of macrophage |
Promote proliferation and invasion |
Purushothaman et al. (2017)
|
PRPS2 |
NSCLC |
Macrophages |
M2 polarization |
Promote DDP resistance |
Liu et al. (2021)
|
miR-203 |
Colorectal cancer |
Monocytes |
M2 polarization/Promote the expression of M2 markers |
Distant metastasis |
Takano et al. (2017)
|
miR-145 |
Colorectal cancer cells |
Macrophage-like cells |
M2-like phenotype/Downregulate histone deacetylase 11 |
Modulate M2-like macrophage polarization and tumor progression |
Shinohara et al. (2017)
|
miR-29a-3p |
Oral squamous cell carcinoma |
Macrophages |
M2 polarization/Activate SOCS1/STAT6 signals |
Promote tumor growth |
Cai et al. (2019)
|
miR-301a-3p |
Hypoxic pancreatic cancer cells |
Macrophages |
M2 polarization/Activate the PTEN/PI3K signaling pathway |
Facilitate the invasion, migration and EMT; increase metastatic ability |
Wang et al. (2018)
|
miR-155/miR-125b-2 |
Panc-1 cells |
M1 macrophages |
Trigger M1 to M2 polarization/increase M2 markers/decrease M1 markers |
Enhance antigen presentation/T-cell activation/tumor destruction |
(Su et al., 2016) |
M2 macrophages |
Repolarize from M2 to M1/high iNOs/Arg1 and IL-1β/Arg1 ratio |
Tumor invasion and metastasis |
miR-21/miR-155 |
Neuroblastoma |
Unpolarized monocytes (prevalent M2) |
Mixed polarization/exosomic mir-21/TLR8-NF-кB/exosomic mir-155/TERF1 signaling pathway |
Development of drug resistance |
Challagundla et al. (2015)
|
miR-146a-5p |
Hepatocellular carcinoma |
Macrophages |
M2 polarization/activate NF-κB signaling/pro-inflammatory factors |
Promote HCC progression |
Yin et al. (2019)
|
miR-16 |
4T1 cells/Myeloma |
Macrophages |
Inhibit TAM infiltration and M2 polarization/IKKα suppression and I-κB accumulation |
Suppress tumor growth |
Jang et al. (2013); Khalife et al. (2019)
|
miR-125b-5p |
Melanoma |
Macrophages |
TAM phenotype/target LIPA |
Induce inflammation and angiogenesis; cell recruitment and survival |
Gerloff et al. (2020)
|
miR-222-3p |
Epithelial ovarian cancer |
Macrophage |
M2 polarization/Inhibit SOCS3/activate STAT3 |
Increase tumor size, microvessels, and lymphatic vessels |
Ying et al. (2016)
|
miR-940 |
Ovarian Cancer |
Macrophages |
M2 polarization |
Promote proliferation and migration |
Chen et al. (2017)
|
miR-21-3p/miR-125b-5p/miR-181d-5p |
Ovarian Cancer |
Undifferentiated macrophages |
M2 polarization/Suppress SOCS4/5/STAT3 pathway |
Tumor progression |
Chen et al. (2018)
|
miR-1246 |
Ovarian Cancer |
Macrophages |
M2 polarization/Target Cav1/p-gp |
Confer chemoresistance and tumor progression |
Kanlikilicer et al. (2018)
|
GOF Mutp53 Colon Cancer Cells |
Macrophages |
M2 polarization/TGF-β activation |
Promote cancer progression and metastasis |
Cooks et al. (2018)
|
Hypoxic glioma |
Macrophage |
M2 polarization/target TERF2IP/activate the STAT3 signaling/inhibit the NF-κB signaling |
Formation of the immunosuppressive microenvironment |
Qian et al. (2020)
|
miR-23a-3p |
Tunicamycin treated HCC cells |
Macrophages |
Elevate PD-L1 in macrophages/inhibit T-cell function through PTEN-AKT pathway |
Tumor cells escape from antitumor immunity |
Liu et al. (2019)
|
miR-130/miR-33 |
Breast cancer |
M2 macrophages/TAMs |
Transform M2 to M1 phenotype |
Inhibit tumor progression |
Moradi-Chaleshtori et al. (2021b); Moradi-Chaleshtori et al., (2021a)
|
TU339 |
Hepatocellular carcinoma |
Macrophages |
M1/M2 polarization/regulate pro-inflammatory cytokine/co-stimulatory molecule expression/phagocytosis |
Regulate cell proliferation |
Li et al. (2018)
|
RPPH1 |
Colorectal cancer |
Macrophages |
M2 polarization/induce EMT; interact with TUBB3; prevent ubiquitination |
Promote metastasis and proliferation |
Liang et al. (2019)
|
BCRT1 |
MDA-MB-231 |
Macrophages |
M2 polarization/modulate migration ability and chemotaxis of macrophages |
Promote cell migration and angiogenesis |
Liang et al. (2020)
|
SOX2-OT |
NSCLC |
Macrophages |
miR-627-3p/Smad axis |
Enhance the EGFR-TKI resistance |
Zhou et al. (2021)
|
CircASAP1 |
Hepatocellular carcinoma |
Macrophages |
Tams infiltration/regulate miR-326/miR-532-5p-MAPK1 signaling/miR-326/miR-532-5p-CSF-1 pathway |
Promote cell proliferation and invasion |
Hu et al. (2019)
|
circ_00074854 |
HCC cell |
Macrophages |
Suppress M2 polarization |
Inhibit migration and invasion |
Wang et al. (2021)
|
circ_0044516 |
Prostate cancer |
— |
Downregulate miR-29a-3p expression |
Promote proliferation and metastasis |
Li et al. (2020)
|
circ-RanGAP1 |
Gastric cancer |
— |
miR-877-3p/VEGFA axis |
Promotes progression |
Lu et al. (2020)
|
Cdr1 |
Ovarian cancer |
— |
miR-1270/SCAI signaling pathway |
sensitize ovarian cancer to cisplatin |
Zhao et al. (2019)
|
circRNAs_102481 |
NSCLC |
— |
miRNA-30a-5p/ROR1 axis |
Contribute to EGFR-TKIs resistance |
Yang et al. (2021)
|
Arachidonic Acid |
Aspc-1 |
Macrophages |
M2-like phenotype/PGE2 secretion, increased secretion of pro-tumoral, bioactive molecules |
Contribute to tumor progression |
(Linton et al., 2018) |